Nordic Nanovector to Present at Jefferies 2016 London Healthcare Conference
Oslo, Norway, 14 November 2016 Nordic Nanovector ASA (OSE: NANO), a biotechnology company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology, announces that members of its management team will participate at: Jefferies 2016 London Healthcare Conference (16-17 November, London, UK) Chief Executive Officer, Luigi Costa, will present an overview of the company, including an introduction to Betalutin®, a potential first-in-class treatment for non-Hodgkin lymphoma, its development strategy, key milestones and market opportunities.